【24h】

TRPS and Migraine

机译:TRPS和偏头痛

获取原文
       

摘要

Migraine is a highly prevalent, disabling neurovascular disorder characterized by a combination of headache,nausea and altered sensory processing such as photophobia. Migraine has a strong genetic background but the molecularpathways that result in a migraine attack, and the role of various triggers, are poorly understood. The throbbing andpulsating pain associated with the headache phase of migraine attack implies an important role for the nociceptiveactivation of trigeminal intracranial afferents that contain calcitonin gene-related peptide (CGRP). Neurogenicinflammation triggered by the release of CGRP is now recognized as a significant underlying event in migraine. Indeed,CGRP receptor antagonists, the so-called “gepants”, have already proved effective in clinical trials as novel, migrainespecificdrugs. An alternative therapeutic approach is the modulation of CGRP release. As potential targets, the transientreceptor potential (TRP) channels expressed by a subpopulation of CGRP-containing nociceptive primary sensory neuronsare gaining increasing prominence, principally because of the recent discovery of a variety of endogenous and exogenousTRP agonists known to induce migraine attack as well as their emerging role in neuropeptide release. The present reviewfocuses on the potential role of the different TRP channels, especially TRPV1, in the migraine mechanism.
机译:偏头痛是一种高度流行的致残性神经血管疾病,其特征是头痛,恶心和感觉过程的改变,例如畏光。偏头痛具有很强的遗传背景,但对导致偏头痛发作的分子途径以及各种触发因素的作用知之甚少。与偏头痛发作的头痛阶段相关的搏动性和搏动性疼痛暗示了含有降钙素基因相关肽(CGRP)的三叉神经颅内传入神经团的伤害感受激活的重要作用。现已认识到由CGRP释放引发的神经源性炎症是偏头痛中的重要潜在事件。实际上,CGRP受体拮抗剂,即所谓的“ gepant”,已在临床试验中被证明是有效的新型偏头痛特异性药物。另一种治疗方法是调节CGRP的释放。作为潜在的靶点,由包含CGRP的伤害性初级感觉神经元亚群表达的瞬时受体电位(TRP)通道正日益受到关注,这主要是由于最近发现了多种已知可诱发偏头痛发作的内源性和外源性TRP激动剂及其在神经肽释放中新兴的作用。本文的综述集中在不同的TRP通道,尤其是TRPV1在偏头痛机制中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号